Coexistence of parathyroid adenoma and papillary thyroid carcinoma: Experience of a single center

Öz

Objective: Malignant Pleural Mesothelioma (MPM) generally associated with asbestos exposure is a tumor with poor prognosis. Modified Glasgow Prognostic Score (GPS) which may be a prognostic parameter in patients with MPM is a designed based score including increased C-reactive protein (CRP) levels and decreased albumin .In this study we aimed to investigate the effect of GPS score on the prognosis of MPM and the role of other potential factors. Methods: In this retrospective planned study 140 histological diagnosed MPM patients were included. Results: Mean age of 140 MPM patients were 52.92 years (83 male and 57 female). A total of 91 patients had environmental asbestos exposure and exposure time was the 31 years. Symptoms of the patients started approximately 4.8 months before the application. The most frequently seen symptoms were in 125 patients dyspnea, in 94 patients chest pain and in 22 patients weight loss. GPS score of the patients were as follows; 64 patients two, 14 patients one, 22 patients zero. Of the patients, 112 died and 28 were alive. Mean survival time was 14 months. Patients with GPS score 2 lived for 10 months, GPS score 1 lived for 15 and GPS score 0 lived for 18 months. This difference was statistically significant. Furthermore, the male sex and age older than 65 years were found as poor prognostic parameters on the survival. Conclusion: A simple and inexpensive parameter able to be used to estimate the prognosis of MPM patients could not be developed .GPS score increases in inflammatory conditions. GPS is a simple and inexpensive parameter that can be used for detecting the severity of patients with MPM.

Anahtar Kelimeler

• Modified Glasgow Prognostic Score, Malignant Pleural Mesothelioma, Prognosis

Paratiroid adenomu ve papiller tiroid karsinom birlikteliği: Tek merkez deneyimi

Öz

Amaç: Malign Plevral Mezotelyoma (MPM) genel olarak asbest teması ile ilişkili ve kötü prognozlu bir tümördür. MPM hastalarında prognostik bir parametre olabilecek olan Modifiye Glasgow Prognoz Skoru (GPS), artmış C-Reaktif Protein (CRP) ve azalmış albümin düzeyleri temel alınarak hazırlanmış bir skordur. Bu çalışmada GPS skorunun MPM prognozu üzerindeki etkilerini incelemek ve diğer potansiyel etkenlerin rollerini araştırmak amaçlanmıştır. Yöntemler: Retrospektif planlanan bu çalışmaya histopatolojik olarak MPM tanısı konan 140 hasta alındı. Bulgular: Toplam 140 MPM hastasının ortalama yaşı 52,92 yıl idi (83 erkek ve 57 kadın) idi. Toplam 91 hastada çevresel asbest teması saptandı ve temas süresi ise 31 yıldı. Hastaların semptomları başvurudan yaklaşık olarak 4,8 ay önce başlamıştı. En sık saptanan semptomlar ise 125 hastada nefes darlığı, 94 hastada göğüs ağrısı ve 22 hastada kilo kaybıydı. GPS skor değeri olarak 64 hasta 2, 22 hasta 1 ve 14 hasta ise sıfır değerini almışlardır. Çalışmaya alınan hastaların 112\'si vefat etmiş ve 28\'i hayattaydı. Tüm hastaların ortalama yaşam süresi 14 ay idi. GPS skoru 2 olan hastalar 10 ay, 1 olanlar 15 ve sıfır olanlar ise yaklaşık 18 ay yaşamışlardır. Bu fark istatistikî olarak önemli bulunmuştur. Ayrıca erkek cinsiyet ve 65 yaş üstü olmada yaşam süresini kötü etkileyen parametreler olarak bulunmuştur. Sonuç: MPM hastalarının prognozunu tahminde kullanılabilecek basit ve ucuz bir parametre geliştirilememiştir. GPS skoru inflamatuar durumlarda artmaktadır. GPS skoru MPM hastalarının ciddiyetini tespitte kullanılabilecek basit ve ucuz bir parametre olarak görülmektedir.

Anahtar Kelimeler

• Modifiye Glasgow Prognoz Skoru, Malign Plevral Mezotelyoma, Prognoz

Kaynakça

1. Silverberg SJ, Bilezikian JP. Asymptomatic primary hyper- parathyroidism: a medical perspective. Surg Clin North Am 2004;84:787-801.
2. Hedinger C, Williams ED, Sobin LH. The WHO histologi- cal classification of thyroid tumors: A commentatory on the second edition. Cancer 1989;63:908-911.
3. Davies L, Welch HG. Increasing incidence of thyroid can- cer in the United States, 1973-2002. JAMA 2006;18:2164- 2167.
4. Krause U, Olbricht T, Metz K, et al. Coincidence of non- medullary thyroid cancer and hyperparathyroidism. Chirurg 1991;62:536-539.
5. Calcaterra TC, Paglia D. The coexistence of parathyroid ade- noma and thyroid carcinoma. Laryngoscope 1979;89:1166- 1169.
6. Morita SY, Somervell H, Umbricht CB, et al. Evaluation for concomitant thyroid nodules and primary hyperparathy- roidism in patients undergoing parathyroidectomy or thy- roidectomy. Surgery 2008;144:862-866.
7. Kissin M, Bakst H. Co-existing myxedema and hyper- parathyroidism; case report. J Clin Endocrinol Metab 1947;7:152–158.
8. Beus KS, Stack BC Jr. Synchronous thyroid pathology in patients presenting with primary hyperparathyroidism. Am J Otolaryngol 2004;25:308-312.

9. Montenegro FLM, Smith RB, Castro IV, et al. Association of papillary thyroid carcinoma and hyperparathyroidism. Rev Col Bras Cir 2005;32:115-119.
10. Katz AD, Kong LB. Incidental preclinical hyperparathy- roidism identified during thyroid operations. Am Surg 1992; 58:747-749.
11. Ron E, Saftlas AF. Head and neck radiation carcinogene- sis: epidemiologic evidence. Otolaryngol Head Neck Surg 1996;115:403-408.
12. Prinz RA, Barbato AL, Braithwaite SS, et al. Prior irradia- tion and the development of coexistent differentiated thy- roid cancer and hyperparathyroidism. Cancer 1982;49:874- 877.
13. Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA 1990;264:581-584.
14. LiVolsi VA, LoGerfo P, Feind CR. Coexistent parathyroid adenomas and thyroid carcinoma. Can radiation be blamed? Arch Surg 1978;113:285-286.
15. Mihailescu D, Shore-Freedman E, Mukani S, et al. Multiple neoplasms in an irradiated cohort: pattern of occurrence and relationship to thyroid cancer outcome. J Clin Endocri- nol Metab 2002;87:3236-3241.
16. Burmeister LA, Sandberg M, Carty SE, Watson CG. Thy- roid carcinoma found at parathyroidectomy: association with primary, secondary, and tertiary hyperparathyroidism. Cancer 1997;79:1611–1616.
17. dell’Erba L, Baldari S, Borsato N, et al. Retrospective analysis of the association of nodular goiter with primary and secondary hyperparathyroidism. Eur J Endocrinol 2001;145:429–434.
18. Sakata S, Fuwa Y, Komaki T, et al. A case of papillary car- cinoma of the thyroid associated with parathyroid adenoma without hyperparathyroidism. Intern Med 1992;31:459- 462.
19. Maiorano E, Ambrosi A, Giorgino R, et al. Insulin-like growth factor 1 (IGF-1) in multinodular goiters: a possible pathogenetic factor. Pathol Res Pract 1994;190:1012–1016.
20. Freitas JE, Freitas AE. Thyroid and parathyroid imaging. Semin Nucl Med 1994;24:234-245.